ʻO Future Market Insights (FMI), i kāna hōʻike, hoʻolālā i ka honua ka hoʻokuʻu waha ʻana i ka mākeke ʻenehana lawe lāʻau e hoʻopaʻa inoa i kahi hoʻonui kupaianaha ma 7.2% CAGR i ka wā wānana 2017 a i 2027. E ʻoi aku ka mākeke i nā loaʻa kālā he US $ 20,000 Mn ma 2017, a ua manaʻo hou ʻia a hiki i kahi kokoke i US $ 50,000 Mn e 2027-hopena.
Hiki i nā mea hana o ka waha ma ʻAmelika ʻĀkau ke loaʻa i ka bioavailability nui
Manaʻo ka hōʻike a FMI i ʻAmelika ʻĀkau e noho mau i ka mākeke nui loa no ka ʻenehana hoʻokuʻu ʻana i ka lāʻau lapaʻau, me ke kūʻai ʻana i manaʻo ʻia e hōʻea ma kahi o US $ 20,000 Mn e 2027-hopena. ʻO ke ala ʻoi loa o ka hoʻokele lāʻau lapaʻau e nā kauka, koi ʻia ka noi no ka hoʻokuʻu ʻana i ka ʻenehana lawe lāʻau lapaʻau e ʻike i ka piʻi ʻana e nā mea hoʻohana hope ma ʻAmelika ʻAmelika. Eia kekahi, ʻo nā holomua hou i ka hāʻawi ʻana i ka lāʻau lapaʻau i hiki ai i nā mea hana lāʻau paʻa waha ma ʻAmelika ʻAmelika e hoʻokō i ka bioavailability nui ma o ka hoʻohana ʻana i nā kahua hoʻopuka lāʻau hou. Manaʻo ʻia kēia e hoʻokau i ka noi no ka hoʻokuʻu ʻana i ka ʻenehana lawe lāʻau lapaʻau i ka ʻāina.
Kaomi no ka loaʻa ʻana o ka laʻana: https://www.futuremarketinsights.com/reports/sample/rep-gb-4400
Eia nō naʻe, ʻo ka hoʻonui ʻana i nā hana noiʻi e pili ana i nā molekala biologic, a me ko lākou mana i ka mālama ʻana i nā kūlana oncology, i hui pū ʻia me nā hoʻopukapuka aupuni i kēia mau hana noiʻi e manaʻo ʻia e pale i ka ulu ʻana o ka mākeke ma ʻAmelika ʻAmelika. Eia kekahi, ʻo nā pilikia hoʻohālikelike e like me ka juncture o nā manaʻolana o ka mākeke no ka dosing hoʻokahi i kēlā me kēia lā, a me ka ulu ʻana o nā papa hoʻokuʻu hoʻokuʻu ʻia e hāʻawi ana i ka hoʻomāinoino ʻana, i loaʻa i ka ʻenehana lawe lāʻau hoʻokuʻu waha e manaʻo ʻia e hoʻonui i ka ulu ʻana o ka mākeke ma kēia wahi.
ʻO nā mea kemika hou e loaʻa mai ana mai ke kiʻekiʻe throughput screening e alakaʻi i ka ulu ʻana o ka mākeke ma ʻEulopa Komohana
E hoʻopaʻa inoa ʻo Western Europe i ka hoʻonui wikiwiki ʻana i ka mākeke oral controlled release drug delivery market. Kuhi ʻia kēia ulu ʻana i ka luku ʻana o nā mea kemika hou i loaʻa mai ka nānā ʻana i ka throughput kiʻekiʻe, he haʻahaʻa haʻahaʻa a me ka bioavailability. Ua alakaʻi hou kēia i nā mea hana ma kēia wahi e hoʻopukapuka i nā ʻano lawe lāʻau lapaʻau me ka hopena lapaʻau ʻoi aku ka maikaʻi. Ma muli o ke kumu kūʻai ma nā ʻāina ʻEulopa Komohana, ʻo nā ʻenehana e hoʻonui ai i ka bioavailability e hoʻomau i ka ʻōnaehana lawe lāʻau. Kuhi ʻia kēia mau mea e alakaʻi i ka ulu ʻana o ka mākeke ma kēia wahi.
Eia nō naʻe, ʻo ka hapa nui o nā hui lāʻau lapaʻau ma ʻEulopa Komohana he kaulahao lako paʻakikī, ʻaʻole i hoʻohana ʻia a ʻaʻole pono. Hoʻopili ʻia ka paʻakikī o ke kaulahao hoʻolako i ka haʻahaʻa haʻahaʻa a me ke kumu kūʻai. Eia kekahi, ʻo ka hoʻopōkole ʻana i ke ola patent kūpono me nā pali patent he mea paʻakikī nui ia no nā ʻano lāʻau paʻa waha ma kēia ʻāina. Kuhi ʻia nā mea e like me kēia e pale i ka ulu ʻana o ka mākeke ma Western Europe.
Dissolution-Controlled Release System e hoʻomau i ka ʻimi ʻia ma waena o nā ʻenehana hoʻokuʻu lāʻau i ka mākeke
Ma o ka ʻenehana hoʻokuʻu lāʻau, e ʻimi mau ʻia ka ʻōnaehana hoʻokuʻu dissolution-controlled ma ka mākeke, a ukali ʻia e ka diffusion-controlled system release. Loaʻa ka hapa nui o nā formulations generic i loko o ke ʻano ʻano ʻano papa a hahai i ka mīkini hoʻokuʻu i hoʻokuʻu ʻia. ʻO nā loaʻa mai ke kūʻai aku ʻana i ka ʻōnaehana hoʻokuʻu i hoʻokuʻu ʻia e ka dissolution e ʻoi aku ma mua o US $ 10,000 Mn ma 2017. ʻO ka noi no ka ʻōnaehana hāʻawi lāʻau hydrodynamically-balanced e noho lohi i ka mākeke.
Manaʻo ʻia nā ʻano dosage paʻa o ka hoʻokuʻu waha ʻana i ka ʻenehana lawe lāʻau e hoʻomau i ka mana ma ka mākeke, e hoʻonui ana i kahi CAGR kiʻekiʻe hoʻokahi-helu a hiki i 2027. E hoʻopaʻa inoa ka kūʻai ʻana o ka semisolid / wai / suspensions dosage form i kahi CAGR haʻahaʻa haʻahaʻa ma mua o ka paʻa. nā ʻano dosage i ka mākeke a hiki i 2027.
ʻO nā mea pāʻani mākeke koʻikoʻi i ʻike ʻia ma ka hōʻike a FMI ʻo AstraZeneca Plc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Industries Ltd, Abbott Laboratories, Merck & Co. Inc., Novartis AG, Pfizer Inc., Mylan NV, Sanofi, F. Hoffman-La -Roche Ltd., Johnson & Johnson Services, Inc., Vectura Group plc., GlaxoSmithKline plc.
Kaomi e kiʻi i ka TOC hohonu o kēia Hōʻike: https://www.futuremarketinsights.com/reports/oral-controlled-release-drug-delivery-technology-market/table-of-content
E pili ana i ka Māhele mālama ola ma Future Market Insights
Mālama ʻo Future Market Insights i nā ʻoihana, aupuni, nā mea hoʻopukapuka, a me nā mea e pili ana i ka ʻoihana mālama olakino e ʻike a hoʻokūkī i nā mea koʻikoʻi e pili ana i ka hoʻolālā huahana, ka ʻāina hoʻoponopono, ka hoʻomohala ʻenehana, a me nā pilikia koʻikoʻi e hoʻokō ai i ka kūleʻa mau. ʻO kā mākou ala kūʻokoʻa i ka hōʻiliʻili ʻana i ka ʻike mākeke e hoʻolako iā ʻoe i ka hoʻolālā ʻana i nā alahele i hoʻoikaika ʻia no kāu ʻoihana. E ʻike hou aku e pili ana i kā mākou ʻāpana ʻāpana ma aneʻi
About Ka Makahiki Hou (FMI)
ʻO Future Market Insights (FMI) kahi alakaʻi alakaʻi o ka mākeke naʻauao a me nā lawelawe kūkākūkā, e lawelawe ana i nā mea kūʻai aku ma luna o 150 mau ʻāina. Aia ʻo FMI i ke keʻena nui ma Dubai, a loaʻa iā ia nā kikowaena lawe ma UK, US a me India. ʻO nā hōʻike noiʻi mākeke hou a FMI a me ka nānā ʻana i nā ʻoihana e kōkua i nā ʻoihana e hoʻokele i nā pilikia a hana i nā hoʻoholo koʻikoʻi me ka hilinaʻi a me ka maopopo ma waena o ka hoʻokūkū breakneck. Hāʻawi kā mākou hōʻike noiʻi mākeke maʻamau a syndicated i nā ʻike hiki ke alakaʻi i ka ulu hoʻomau. Hoʻomau mau ka hui o nā mea loiloi alakaʻi akamai ma FMI i nā ʻano e kū mai ana a me nā hanana i loko o kahi ākea o nā ʻoihana e hōʻoia i kā mākou mea kūʻai aku e mākaukau no nā pono e ulu nei o kā lākou mea kūʻai.
Kāhea iā mā˚ou:
Nā Hōʻikeʻike o ka Makahiki Hou
Mokuna No: AU-01-H ʻO ka Hale Hōʻikeʻike gula (AU), No Kūkulu: JLT-PH1-I3A,
ʻO Jumeirah Lakes Towers, Dubai,
United Arab Emirates
No nā Nīnau Nīnau: [pale ʻia ka leka uila]
No nā nīnau Media: [pale ʻia ka leka uila]
Paena pūnaewele: https://www.futuremarketinsights.com
He aha e lawe ʻia mai kēia ʻatikala:
- In addition, formulation challenges such as juncture of market expectations for once-daily dosing, and growth of controlled release tablets which impart abuse resistance, incurred in oral controlled release drug delivery technology are expected to further curb growth of the market in this region.
- Solid dosage forms of oral controlled release drug delivery technology are expected to remain dominant in the market, expanding at a high single-digit CAGR through 2027.
- However, increasing research activities related to biologic molecules, and their dominance in treating oncology conditions, coupled with government investments in these research activities are expected to impede the market growth in North America.
